<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357197</url>
  </required_header>
  <id_info>
    <org_study_id>P2020-157</org_study_id>
    <nct_id>NCT04357197</nct_id>
  </id_info>
  <brief_title>Closed-loop Control Mean Arterial Pressure In Intensive Care Patients</brief_title>
  <official_title>Closed-loop Control of Vasopressor Infusion in Critically Ill Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performance of a novel closed-loop (automated)
      vasopressor administration system that delivers norepinephrine using feedback from standard
      hemodynamic monitor (EV1000 Monitor) from Edwards Lifesciences (IRVINE, USA) in critically
      ill patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this protocol, the investigators will report the percentage of case time in hypotension
      (defined as Mean arterial pressure (MAP) &lt; 72mmHg) during a two hours study protocol in
      critically ill patients.

      The target MAP will be set at 80 mmHg, and the definition of hypotension is a MAP &lt; 90% of
      MAP target ( 80 mmHg - 10% = 72 mmHg)

      The investigators want to demonstrate that the closed-loop system can prevent hypotension at
      this specific set point.

      The investigators will test the system in a short series of 15 critically ill patients in the
      ICU setting during a two hours study protocol.

      Participants will receive standard patient care

      Fluids will be given as a baseline crystalloid administration set at 1-2 ml/kg/h
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single prospective single center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of case Time in hypotension (MAP &lt;72 mmHg)</measure>
    <time_frame>During thetwo hours study protocol</time_frame>
    <description>The primary outcome will be the percentage of case time in predefined MAP target</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of case time with MAP &gt;88 mmHg with norepinephrine still running</measure>
    <time_frame>During the two hours study protocol</time_frame>
    <description>overtreatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of vasopressors received</measure>
    <time_frame>During the two hours study protocol</time_frame>
    <description>Amount of vasopressors received (norepinephrine)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Closed-loop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Closed-loop administration of norepinephrine in critically ill patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Closed-loop</intervention_name>
    <description>The system will be tested to see if it can avoid hypotension</description>
    <arm_group_label>Closed-loop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients in the intensive care unit (awake or under sedation)

          -  Requiring norepinephrine to maintain a MAP of 80 mmHg

          -  Equiped with an arterial line

        Exclusion Criteria:

          -  Subjects under 18 years of age

          -  Subject with Atrial Fibrillation

          -  Subjects who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Joosten, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ERASME</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Joosten, MD PhD</last_name>
    <phone>025553111</phone>
    <phone_ext>025553111</phone_ext>
    <email>joosten-alexandre@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>barvais luc, MD PhD</last_name>
    <phone>025553111</phone>
    <phone_ext>025553111</phone_ext>
    <email>luc.barvais@ulb.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erasme</name>
      <address>
        <city>Brussels</city>
        <state>Anderlecth</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Joosten</last_name>
      <phone>025553111</phone>
      <phone_ext>025553111</phone_ext>
      <email>joosten-alexandre@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Barvais Luc</last_name>
      <phone>025553111</phone>
      <phone_ext>025553111</phone_ext>
      <email>Luc.barvais@ulb.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 19, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>July 4, 2020</last_update_submitted>
  <last_update_submitted_qc>July 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Alexandre Joosten, MD PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

